IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q4 2022 Results Conference Call February 6, 2023 8:30 AM ET Company Participants Jay Mazelsky - President and Chief Executive Officer Brian McKeon - Chief Financial Officer John Ravis - Vice President, Investor Relations Conference Call Participants Nathan Rich - Goldman Sachs Chris Schott - JPMorgan Erin Wright - Morgan Stanley Michael Ryskin - Bank of America Jon Block - Stifel Ryan Daniels - William Blair Operator Good morning, and welcome to the IDEXX Laboratories ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) One IDEXX Drive Westbrook Maine 04092 (Address of principal executive offices) (ZIP Code) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 ...

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants Brian McKeon - CFO Jay Mazelsky - CEO Conference Call Participants Chris Schott - JPMorgan Erin Wright - Morgan Stanley Jon Block - Stifel Nathan Rich - Goldman Sachs David Westenberg - Piper Sandler Ryan Daniels - William Blair Elliot Wilbur - Raymond James Operator Good morning, and welcome to the IDEXX Laboratories Third Quarter 2022 Earnings Conference Call. As a reminder, today's ...

IDEXX Q3 2022 Earnings Highlights (NASDAQ: IDXX) Revenue Operating Profit Diluted Earnings Per Share +4% +6% +8% Reported growth: of Revenue Reported growth: Organic growth: YoY change in basis points: CAG Diagnostics Recurring Organic growth: Reported Comparable Comparable growth: +9% +120 bps +13% | --- | --- | --- | --- | --- | --- | --- | --- | --- | |---------------------------------------------------------------|-------------|----------------------------------|--------------------------------|-------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________. COMMISSION FILE NUMBER: 000-19271 Securities Registered pursuant to Section 12(b) of the Act: | Title of each class | Tradi ...

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q2 2022 Earnings Conference Call August 2, 2022 8:30 AM ET Company Participants Brian McKeon - Executive Vice President, Chief Financial Officer & Treasurer Jay Mazelsky - President & Chief Executive Officer Conference Call Participants Michael Ryskin - Bank of America Chris Schott - JPMorgan Erin Wright - Morgan Stanley Jon Block - Stifel Elliot Wilbur - Raymond James Ryan Daniels - William Blair Operator Good morning, and welcome to the IDEXX Laboratories Second Quar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________. COMMISSION FILE NUMBER: 000-19271 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) | Title ...

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Brian McKeon - CFO, EVP & Treasurer Jonathan Mazelsky - President, CEO & Director Conference Call Participants Christopher Schott - JPMorgan Chase & Co Michael Ryskin - Bank of America Merrill Lynch Erin Wright - Morgan Stanley Jonathan Block - Stifel, Nicolaus & Company Nathan Rich - Goldman Sachs Group Balaji Prasad - Barclays Bank Operator Good morning, and welcome to the IDEXX Laboratories ...

| --- | --- | --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | IDEXX Laboratories, Inc. Raymond James 43rd Annual Institutional Investors Conference | | | | | | | | | | | | | | | | Jay Mazelsky President and Chief Executive Officer March 7, 2022 | | | | | | | | | | | | | | | Safe Harbor Disclaimer The following information contains forward-looking statements within the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________. COMMISSION FILE NUMBER: 0-19271 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 01-039372 ...